- CTOT-C NIH/ NIAID Grant (1U01 AI077821)
Development of Transplant Strategies Uniquely Responsive to the Needs of Children
Major goal: Investigate innate alloimmune responses after organ transplantation in children.
- NIH/NIAID (U01 AI084150-01) CTOT Preserving Renal Function & Protective Immunity Via Anti-FLA1-Based CNI Avoidance
Major goal: To investigate efalizumab as an alternative to Cni-based immunosuppression in kidney and liver transplantation to preserve renal function, avoid diabetes and reduce cardiovascular risk.
- Wyeth CNI-W Study
Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil and Corticosteroids Versus an Historic Control Popualtion Receiving Calcineurin Inhibitors Based Immunosuppression.
Major goal: To study the hypothesis that the use of Sirolimus (SRL) in pediatric kidney transplantation will allow the withdrawal of Calcineurin inhibitor and improve kidney function and long term survival in patients.
- IST Genentech Grant (IgA Nephropathy)
Randomized Study of Rituxan vs Standard of Care for treatment of Non-Crescentic IgA Nephropathy
Major goal: A clinical study of the efficacy and safety of Rituxan for treatment of IgA Nephropathy
- Alexion Pharmaceuticals
An open-label, multi-center controlled clinical trial of Eculizumab in adolescent patients with plasma therapy-resistant or sensitive atypical hemolytic uremic syndrome (AHUS).
Major goal: to determine if eculizumab is safe and effective in the treatment of aHUS in adolescent patients who have not been adequatedly helped or have suffered side effects from the current available treatments.
- Raptor Therapeutics Inc
A Pharmacokinetic and pharmacodynamic study to determine the safety and efficacy of Cysteamine Bitartrate delayed-release capsules (RP103), compared to Cystagon in patients with nephropathic cystinosis.
Major goal: to determine the 2 weeks of treatment at steady-state with Q12H dosing of RP103 results in comparable depletion of white blood cell cystine levels relative to Q6H dosing of Cystagon.
- Randomized Study of Desensitization for Pediatric Kidney Transplant Recipients
A prospective randomized single-center study of high dose IVIG vs. Rituxan/IVIG for highly sensitized pediatric patients for successful renal transplantation.
- Steroid-Free Randomized Protocol of Daclizumab vs. Thymoglobulin Iinduction
A prospective randomized multicenter study of steroid free immunosuppression for low risk pediatric kidney transplant recipients.
- Tolerance Registry (ISOrTT) for Operationally Tolerant Liver Transplant Recipients
- Boretizumib for Highly Sensitized Transplant Recipients: Rejection and Desensitization